SG10202012182YA - Compositions and methods for treating rheumatoid arthritis - Google Patents

Compositions and methods for treating rheumatoid arthritis

Info

Publication number
SG10202012182YA
SG10202012182YA SG10202012182YA SG10202012182YA SG10202012182YA SG 10202012182Y A SG10202012182Y A SG 10202012182YA SG 10202012182Y A SG10202012182Y A SG 10202012182YA SG 10202012182Y A SG10202012182Y A SG 10202012182YA SG 10202012182Y A SG10202012182Y A SG 10202012182YA
Authority
SG
Singapore
Prior art keywords
antibody
subject
rheumatoid arthritis
weeks
arthritis
Prior art date
Application number
SG10202012182YA
Other languages
English (en)
Inventor
Deborah Bauer
Alexander Boddy
Neil Graham
Yong Lin
Janie Parrino
Rahul Patel
Adelsberg Janet Van
Hoogstraten Hubert Van
Original Assignee
Sanofi Biotechnology
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16305253.3A external-priority patent/EP3216461A1/en
Application filed by Sanofi Biotechnology, Regeneron Pharma filed Critical Sanofi Biotechnology
Publication of SG10202012182YA publication Critical patent/SG10202012182YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10202012182YA 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis SG10202012182YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305253.3A EP3216461A1 (en) 2016-03-07 2016-03-07 Compositions and methods for treating rheumatoid arthritis
EP16170664 2016-05-20
EP16306111 2016-09-05

Publications (1)

Publication Number Publication Date
SG10202012182YA true SG10202012182YA (en) 2021-01-28

Family

ID=58387910

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202012182YA SG10202012182YA (en) 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis
SG11201807614SA SG11201807614SA (en) 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201807614SA SG11201807614SA (en) 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis

Country Status (18)

Country Link
US (1) US20190100585A1 (enExample)
EP (1) EP3426295A1 (enExample)
JP (2) JP7166925B2 (enExample)
KR (3) KR20230093522A (enExample)
CN (1) CN109069642A (enExample)
AU (2) AU2017229364A1 (enExample)
BR (1) BR112018067851A2 (enExample)
CA (1) CA3016880A1 (enExample)
CL (1) CL2018002559A1 (enExample)
CR (1) CR20180465A (enExample)
EA (1) EA201892005A1 (enExample)
IL (2) IL308539A (enExample)
MX (2) MX2018010815A (enExample)
PH (1) PH12018501894A1 (enExample)
SG (2) SG10202012182YA (enExample)
TN (1) TN2018000312A1 (enExample)
TW (3) TWI747885B (enExample)
WO (1) WO2017155990A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
MX2020005630A (es) * 2017-11-30 2020-08-20 Bio Thera Solutions Ltd Formulacion liquida de anticuerpos humanizados para el tratamiento de enfermedades relacionadas con il-6.
KR20260109977A (ko) 2018-08-29 2026-07-13 리제너론 파아마슈티컬스, 인크. 류마티스성 관절염을 갖는 대상체를 치료하기 위한 방법 및 조성물
JP7542543B2 (ja) 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
JP2022545312A (ja) 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー 関節リウマチの診断及び処置の方法
CA3142710A1 (en) * 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
WO2023020563A1 (en) * 2021-08-18 2023-02-23 Bio-Thera Solutions, Ltd. Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases
WO2026047197A1 (en) 2024-08-30 2026-03-05 Sanofi Biotechnology Differential biomarkers for anti-interleukin-6 and anti-tumor necrosis factor-α treatment response in rheumatoid arthritis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
CA2817619A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
KR20230155586A (ko) * 2013-11-22 2023-11-10 사노피 바이오테크놀로지 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법

Also Published As

Publication number Publication date
KR20180114955A (ko) 2018-10-19
MX2023014841A (es) 2024-01-15
TWI819435B (zh) 2023-10-21
TWI747885B (zh) 2021-12-01
WO2017155990A1 (en) 2017-09-14
TW202239767A (zh) 2022-10-16
KR20230093522A (ko) 2023-06-27
IL308539A (en) 2024-01-01
AU2017229364A1 (en) 2018-10-25
SG11201807614SA (en) 2018-10-30
NZ746988A (en) 2023-10-27
TW201808993A (zh) 2018-03-16
JP2023011711A (ja) 2023-01-24
AU2024203011A1 (en) 2024-07-11
JP2019507775A (ja) 2019-03-22
KR20260049875A (ko) 2026-04-14
CL2018002559A1 (es) 2019-03-01
IL261515B2 (en) 2024-04-01
CR20180465A (es) 2019-03-04
IL261515B1 (en) 2023-12-01
EP3426295A1 (en) 2019-01-16
EA201892005A1 (ru) 2019-02-28
MX2018010815A (es) 2019-01-10
CA3016880A1 (en) 2017-09-14
JP7166925B2 (ja) 2022-11-08
US20190100585A1 (en) 2019-04-04
TN2018000312A1 (en) 2020-01-16
JP7745529B2 (ja) 2025-09-29
CN109069642A (zh) 2018-12-21
TW202419103A (zh) 2024-05-16
PH12018501894A1 (en) 2019-05-15
IL261515A (en) 2018-10-31
BR112018067851A2 (pt) 2019-02-05

Similar Documents

Publication Publication Date Title
IL278004A (en) Methods and preparations for treating conditions related to aging
PT3490582T (pt) Composições para utilização no tratamento da mielofibrose
IL251721A0 (en) Preparations and methods for the treatment of diseases of the central nervous system
GB201718801D0 (en) Compositions and methods for inhibiting factor D
IL261515A (en) Compositions and methods for treating rheumatoid arthritis
PL3206493T3 (pl) Kompozycje i sposoby leczenia zaburzeń OUN
PL3224269T3 (pl) Kompozycje i sposoby leczenia zaburzeń OUN
PL3250210T3 (pl) Kompozycje i sposoby leczenia zaburzeń OUN
GB2535937B (en) Arginase I for treating rheumatoid arthritis
ZA201805490B (en) Methods and compositions for treating hyperhidrosis
PL3071230T3 (pl) Kompozycje do leczenia reumatoidalnego zapalenia stawów oraz sposoby ich stosowania
AU2015263874B2 (en) Methods and devices for treating pelvic conditions
IL280824A (en) Methods and compositions for the treatment of rheumatoid arthritis patients
IL264167A (en) Preparations and methods for the treatment of frontotemporal dementia
SG11201803485UA (en) Method for producing silazane-siloxane copolymers and the use of such copolymers
IL291266A (en) Preparations and methods for treating infections
ZA201703771B (en) Compositions and methods for treating hyperkalemia
PT3220908T (pt) Composições e métodos para o tratamento da endometriose
ZA201605109B (en) Compositions and methods for treating neutropenia
IL266361A (en) Methods and preparations for the treatment of cartilage damage and arthritis
EP3255994A4 (en) Methods and materials for assessing and treating arthritis
PT3071230T (pt) Composições para o tratamento da artrite reumatoide e métodos de utilização das mesmas
ZA201903005B (en) Methods and compositions for treating atopic dermatitis
HK1260497A1 (en) Compositions and methods for treating rheumatoid arthritis
HK40009682A (en) Methods and compositions for treating myelofibrosis